Амилоидоз сердца: консенсус Евразийской ассоциации кардиологов (ЕАК)

Амилоидоз является системным заболеванием, поражающим не только сердечно-сосудистую систему. В документе наиболее широко обсуждается этиология, патогенез, особенности клинического течения двух типов амилоидоза AL- и ATTR. Суммированы данные обновленных международных протоколов и рекомендаций по диагностике амилоидоза. Представлен краткий обзор по методам инвазивной и неинвазивной диагностики и их сочетаниям, для каждой из диагностических опций и инструментов приводится анализ доказательной базы. В статье описан адаптированный алгоритм последовательной диагностики и дифференциальной диагностики пациентов с подозрением на АКМП с учетом сочетания клинических проявлений и данных обследования. В статье освящена проблема как специфического лечения AL- и ATTR, так и симптоматической терапии, как сердечной недостаточности, нарушений ритма и проводимости, так и неврологических проявлений. Документ будет полезен как врачам первичного звена, так и узким специалистам: кардиологам, неврологам, гематологам и нефрологам.

1. Buxbaum JN, Dispenzieri A, Eisenberg DS, Fändrich M, Merlini G, Saraiva MJM, Sekijima Y, Westermark P. Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee. Amyloid. 2022 Dec;29(4):213-219. https://doi.org/10.1080/13506129.2022.2147636

2. Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis. Circulation. 2017 Apr 4;135(14):13571377. https://doi.org/10.1161/CIRCULATIONAHA.116.024438

3. Madan N, Kalra D. Clinical evaluation of infiltrative cardiomyopathies resulting in heart failure with preserved ejection fraction. Rev Cardiovasc Med. 2020 Jun 30;21(2):181-190, https://doi.org/10.31083/j.rcm.2020.02.65

4. Lousada I, Comenzo RL, Landau H, Guthrie S, Merlini G. Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium. Adv Ther. 2015 Oct;32(10):920-8. https:// doi.org/10.1007/s12325-015-0250-0

5. Papoutsidakis N, Miller EJ, Rodonski A, Jacoby D. Time Course of Common Clinical Manifestations in Patients with Transthyretin Cardiac Amyloidosis: Delay From Symptom Onset to Diagnosis. J Card Fail. 2018 Feb;24(2):131-133. https://doi.org/10.1016/j.cardfail.2017.12.005

6. Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387(10038):2641–54. https://doi.org/10.1016/S0140-6736(15)01274-X

7. Obi CA, Mostertz WC, Griffin JM, Judge DP. ATTR Epidemiology, Genetics, and Prognostic Factors. Methodist Debakey Cardiovasc J. 2022 Mar 14;18(2):17-26. https://doi.org/10.14797/mdcvj.1066

8. Poli L, Labella B, Cotti Piccinelli S, Caria F, Risi B, Damioli S, Padovani A, Filosto M. Hereditary transthyretin amyloidosis: a comprehensive review with a focus on peripheral neuropathy. Front Neurol. 2023 Oct 5;14:1242815. https://doi.org/10.3389/fneur.2023.1242815

9. Bart NK, Thomas L, Korczyk D, Atherton JJ, Stewart GJ, Fatkin D. Amyloid Cardiomyopathy. Heart Lung Circ. 2020 Apr;29(4):575-583. https://doi.org/10.1016/j.hlc.2019.11.019

10. , Witteles RM, Bokhari S, Damy T, Elliott PM, Falk RH, Fine NM, Gospodinova M, Obici L, Rapezzi C, Garcia-Pavia P. Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice. JACC Heart Fail. 2019 Aug;7(8):709-716. https://doi.org/10.1016/j.jchf.2019.04.010

11. Bukhari S. Cardiac amyloidosis: state-of-the-art review. J Geriatr Cardiol. 2023 May 28;20(5):361-375. https://doi.org/10.26599/1671-5411.2023.05.006

12. Porcari A, Razvi Y, Masi A, Patel R, Ioannou A, Rauf MU, Hutt DF, Rowczenio D, Gilbertson J, Martinez-Naharro A, Venneri L, Whelan C, Lachmann H, Wechalekar A, Quarta CC, Merlo M, Sinagra G, Hawkins PN, Fontana M, Gillmore JD. Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy. Eur J Heart Fail. 2023 Apr;25(4):515-524. https://doi.org/10.1002/ejhf.2776

13. Aung N, Nicholls HL, Chahal CAA, Khanji MY, Rauseo E, Chadalavada S, Petersen SE, Munroe PB, Elliott PM, Lopes LR. Prevalence, Cardiac Phenotype, and Outcomes of Transthyretin Variants in the UK Biobank Population. JAMA Cardiol. 2024 Nov 1;9(11):964-972. https://doi.org/10.1001/jamacardio.2024.2190

14. Chandrashekar P, Alhuneafat L, Mannello M, Al-Rashdan L, Kim MM, Dungu J, Alexander K, Masri A. Prevalence and Outcomes of p.Val142Ile TTR Amyloidosis Cardiomyopathy: A Systematic Review. Circ Genom Precis Med. 2021 Oct;14(5):e003356. https://doi.org/10.1161/CIRCGEN.121.003356

15. Maurer MS, Bokhari S, Damy T, Dorbala S, Drachman BM, Fontana M, Grogan M, Kristen AV, Lousada I, Nativi-Nicolau J, Cristina Quarta C, Rapezzi C, Ruberg FL, Witteles R, Merlini G. Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. Circ Heart Fail. 2019 Sep;12(9):e006075. https://doi.org/10.1161/CIRCHEARTFAILURE.119.006075

16. Никитин С.С., Бардаков С.Н., Супонева Н.А. и др. Фенотипическая гетерогенность и особенности диагностики транстиретинового амилоидоза с полинейропатией. Нервно-мышечные болезни 2021;11(3):12–36. https://doi.org/10.17650/2222-8721-2021-11-3-12-36

17. Zaida L Almeida et al. Transthyretin mutagenesis: impact on amyloidogenesis and disease. Crit Rev Clin Lab Sci. 2024 Nov;61(7):616-640, https://doi.org/10.1080/10408363.2024.2350379

18. Hellman U, Alarcon F, Lundgren HE, Suhr OB, Bonaiti-Pellie C, Plante-Bordeneuve V (2008) Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid 15:181–186. https://doi.org/10.1080/13506120802193720

19. WHO classification of Tumours. Haematolymphoid tumours. Tissues. 5-th Edition. 2024. P.930.

20. Ravichandran S, Lachmann HJ, Wechalekar AD. Epidemiologic and Survival Trends in Amyloidosis, 1987-2019. N Engl J Med. 2020, 16; 382(16):1567-1568. https://doi.org/10.1056/nejmc1917321

21. Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016. 25; 387(10038):2641-2654. https://doi.org/10.1016/s0140-6736(15)01274-x

22. Kumar N, Zhang NJ, Cherepanov D, Romanus D, Hughes M, Faller DV. Global epidemiology of amyloid light-chain amyloidosis. Orphanet J Rare Dis. 2022. 19; 17(1):278. https://doi.org/10.1186/s13023-022-02414-6

23. Baker KR. Light Chain Amyloidosis: Epidemiology, Staging, and Prognostication. Methodist Debakey Cardiovasc J. 2022. 14; 18(2):27-35. https://doi.org/10.14797/mdcvj.1070

24. Palladini G, Schönland S, Merlini G, Milani P, Jaccard A, Bridoux F, Dimopoulos MA, Ravichandran S, Hegenbart U, Roeloffzen W, Cibeira MT, Agis H, Minnema MC, Bergantim R, Hájek R, João C, Leonidakis A, Cheliotis G, Sonneveld P, Kastritis E, Wechalekar A. The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018. Blood Cancer J. 2023 Jan 25;13(1):19. https://doi.org/10.1038/s41408-023-00789-8

25. Manwani R, Cohen O, Sharpley F, Mahmood S, Sachchithanantham S, Foard D, Lachmann HJ, Quarta C, Fontana M, Gillmore JD, Whelan C, Hawkins PN, Wechalekar AD. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood. 2019. 19;134(25):2271-2280. https://doi.org/10.1182/blood.2019000834

26. Хышова В. А., Рехтина И. Г., Фирсова М. В., Менделеева Л. П. Трудности в диагностике первичного AL-амилоидоза. Онкогематология 2021;16(3):74-82. https://doi.org/10.17650/1818-8346-2021-16-3-74-82

27. Escher F, Senoner M, Doerler J, et al. When and how do patients with cardiac amyloidosis die? Clin Res Cardiol. 2020;109:78-88. https://doi.org/10.1007/s00392-019-01490-2

28. Lousada I, Comenzo RL, Landau H, Guthrie S, Merlini G. Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium. Adv Ther. 2015. 32(10):920-8. https://doi.org/10.1007/s12325-015-0250-0

29. Hipp MS, Park SH, Hartl FU. Proteostasis impairment in proteinmisfolding and -aggregation diseases. Trends Cell Biol 2014; 24:506-514. https://doi.org/10.1016/j.tcb.2014.05.003

30. Muchtar E, Dispenzieri A, Leung N, et al. Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. Leukemia. 2018; 32(10):2240-2249. https://doi.org/10.1038/s41375-018-0060-x

31. Shi J, Guan J, Jiang B et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a noncanonical p38alpha MAPK pathway. Proc Natl Acad Sci U S A 2010; 107(9):4188-4193. https://doi.org/10.1073/pnas.0912263107

32. Mishra S, Guan J, Plovie E et al. Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish. Am J Physiol Heart Circ Physiol 2013; 305(1):H95-103. https://doi.org/10.1152/ajpheart.00186.2013

33. Witteles RM, Bokhari S, Damy T, Elliott PM, Falk RH, Fine NM, et al. Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice. JACC Hear Fail. 2019;7(8):709-716. https://doi.org/10.1016/j.jchf.2019.04.010

34. Yilmaz A, Bauersachs J, Bengel F, Büchel R, Kindermann I, Klingel K, et al. Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK). Clin Res Cardiol. 2021;110(4):479–506. Available from: https://doi.org/10.1007/s00392-020-01799-3

35. Younis M, Ogbu I, Kalra DK. Optimizing drug therapies in cardiac amyloidosis. Pharmacol Ther. 2025 Jan;265:108758. https://doi.org/10.1016/j.pharmthera.2024

36. Porcari A, Fontana M, Gillmore JD. Transthyretin cardiac amyloidosis. Cardiovasc Res. 2023 Feb 3;118(18):3517-3535. https://doi.org/10.1093/cvr/cvac119

37. Rapezzi C, Quarta CC, Riva L, Longhi S, Gallelli I, Lorenzini M, Ciliberti P, Biagini E, Salvi F, Branzi A. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol. 2010 Jul;7(7):398-408. https://doi.org/10.1038/nrcardio.2010.67

38. Merlini G, Dispenzieri A, Sanchorawala V, Schönland SO, Palladini G, Hawkins PN, Gertz MA. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018 Oct 25;4(1):38. https://doi.org/10.1038/s41572-018-0034-3

39. Чайковская О.Я., Саидова М.А., Добровольская С.В., Шошина А.А., Насонова С.Н., Жиров И.В., Терещенко С.Н. Эхокардиографические особенности фенотипов амилоидной кардиомиопатии у пациентов с различными типами амилоидоза. Терапевтический архив. 2025;97(4):315-321. https://doi.org/10.26442/00403660.2025.04.203168

40. Brito D, Albrecht FC, De Arenaza DP, Bart N, Better N, CarvajalJuarez I et al. World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). Global Heart 2023;18(1):59. https://doi.org/10.5334/gh.1262

41. Jaiswal V, Agrawal V, Khulbe Y, Hanif M, Huang H, Hameed M et al.Cardiac amyloidosis and aortic stenosis: a state-of-the-art review. European Heart Journal Open. 2023;3(6):oead106. https://doi.org/10.1093/ehjopen/oead106

42. Ahammed MR, Ananya FN. Cardiac Amyloidosis: A Comprehensive Review of Pathophysiology, Diagnostic Approach, Applications of Artificial Intelligence, and Management Strategies. Cureus. 2024 Jul 2;16(7):e63673. https://doi.org/10.7759/cureus.63673

43. Martinez-Naharro A, Gonzalez-Lopez E, Corovic A, Mirelis JG, Baksi AJ, Moon JC, Garcia-Pavia P, Gillmore JD, Hawkins PN, Fontana M. High Prevalence of Intracardiac Thrombi in Cardiac Amyloidosis. J Am Coll Cardiol. 2019 Apr 9;73(13):1733-1734. https://doi.org/10.1016/j.jacc.2019.01.035

44. Napolitano A, De Michieli L, Sinigiani G, Berno T, Cipriani A, Spiezia L. Thromboembolic and Bleeding Events in Transthyretin Amyloidosis and Coagulation System Abnormalities: A Review. J Clin Med. 2023 Oct 20;12(20):6640, https://doi.org/10.3390/jcm12206640

45. Fotiou D, Theodorakakou F, Spiliopoulou S, Gavriatopoulou M, Migkou M, Kanellias N, Eleutherakis-Papaiakovou E, Malandrakis P, Dialoupi I, Roussou M, Ntanasis-Stathopoulos I, Terpos E, Dimopoulos MA, Kastritis E. Thrombotic and bleeding complications in patients with AL amyloidosis. Br J Haematol. 2024 May;204(5):1816-1824. https://doi.org/10.1111/bjh.19331

46. Chacko L, Kotecha T, Ioannou A, Patel N, Martinez-Naharro A, Razvi Y, Patel R, Massa P, Venneri L, Brown J, Porcari A, Knott K, Manisty C, Knight D, Lockie T, Rakhit R, Lachmann H, Wechelakar A, Whelan C, Ponticos M, Moon J, González A, Gilbertson J, Riefolo M, Leone O, Xue H, Hawkins P, Kellman P, Gillmore J, Fontana M. Myocardial perfusion in cardiac amyloidosis. Eur J Heart Fail. 2024 Mar;26(3):598-609. https://doi.org/10.1002/ejhf.3137

47. Itzhaki Ben Zadok O, Vaxman I, Hoss S, Talmor-Barkan Y, Steinmetz T, Raanani P, Kornowski R, Hamdan A. Coronary Artery Disease and Microvascular Ischemia in Patients with Cardiac Amyloidosis. Acta Haematol. 2025;148(4):452-461. https://doi.org/10.1159/000542510

48. Bashir Z, Younus A, Dhillon S, Kasi A, Bukhari S. Epidemiology, diagnosis, and management of cardiac amyloidosis. J Investig Med. 2024 Oct;72(7):620-632. https://doi.org/10.1177/10815589241261279

49. Adams D, Ando Y, Beirão JM, Coelho T, Gertz MA, Gillmore JD, Hawkins PN, Lousada I, Suhr OB, Merlini G. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol. 2021; 268(6):2109-2122. PMID: 31907599; PMCID: PMC8179912. https://doi.org/10.1007/s00415-019-09688-0

50. Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, Lewis WD, Obici L, Planté-Bordeneuve V, Rapezzi C, Said G, Salvi F. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013 Feb 20;8:31. PMID: 23425518; PMCID: PMC:3584981. https://doi.org/10.1186/1750-1172-8-31

51. Никитин С.С., Бардаков С.Н., Супонева Н.А. и др. Фенотипическая гетерогенность и особенности диагностики транстиретинового амилоидоза с полинейропатией. Нервно-мышечные болезни 2021;11(3):12-36. https://doi.org/10.17650/2222-8721-2021-11-3-12-36

52. Лысенко (Козловская) Л.В., Рамеев В.В., Моисеев С.В. и др. Клинические рекомендации по диагностике и лечению системного амилоидоза. Клин фармакол тер 2020;29(1):13-24. https://doi.org/10.32756/0869-5490-2020-1-13-24

53. Зиновьева О.Е., Сафиулина Э.И. Транстиретиновая амилоидная полинейропатия: патогенез, клинические особенности, перспективы лечения. Manage pain. 2017;4:12-5.

54. Адян Т.А., Поляков А.В. Наследственный транстиретиновый амилоидоз. Нервно-мышечные болезни. 2019;9(4):12-25. https://doi.org/10.17650/2222-8721-2019-9-4-12-25

55. Mariani LL, Lozeron P, Theaudin M et al (2015) Genotypephenotype correlation and course of transthyretin familial amyloid polyneuropathies in France. Ann Neurol 78:901-916. https://doi.org/10.1002/ana.24519

56. Coelho T, Vinik A, Vinik EJ, Tripp T, Packman J, Grogan DR (2017) Clinical measures in transthyretin familial amyloid polyneuropathy. Muscle Nerve 55:323-332. https://doi.org/10.1002/mus.25257

57. Milandri A, Farioli A, Gagliardi C, Longhi S, Salvi F, Curti S, Foffi S, Caponetti AG, Lorenzini M, Ferlini A, Rimessi P, Mattioli S, Violante FS, Rapezzi C. Carpal tunnel syndrome in cardiac amyloidosis: implications for early diagnosis and prognostic role across the spectrum of aetiologies. Eur J Heart Fail. 2020 Mar;22(3):507-515. https://doi.org/10.1002/ejhf.1742

58. Sperry BW, Reyes BA, Ikram A, Donnelly JP, Phelan D, Jaber WA, Shapiro D, Evans PJ, Maschke S, Kilpatrick SE, Tan CD, Rodriguez ER, Monteiro C, Tang WHW, Kelly JW, Seitz WH Jr, Hanna M. Tenosynovial and Cardiac Amyloidosis in Patients Undergoing Carpal Tunnel Release. J Am Coll Cardiol. 2018 Oct 23;72(17):2040-2050, https://doi.org/10.1016/j.jacc.2018.07.092

59. Westin O, Fosbøl EL, Maurer MS, Leicht BP, Hasbak P, Mylin AK, Rørvig S, Lindkær TH, Johannesen HH, Gustafsson F. Screening for Cardiac Amyloidosis 5 to 15 Years After Surgery for Bilateral Carpal Tunnel Syndrome. J Am Coll Cardiol. 2022 Sep 6;80(10):967-977. https://doi.org/10.1016/j.jacc.2022.06.026

60. , Maurer MS, Smiley D, Simsolo E, Remotti F, Bustamante A, Teruya S, Helmke S, Einstein AJ, Lehman R, Giles JT, Kelly JW, Tsai F, Blaner WS, Brun PJ, Riesenburger RI, Kryzanski J, Varga C, Patel AR. Analysis of lumbar spine stenosis specimens for identification of amyloid. J Am Geriatr Soc. 2022 Dec;70(12):3538-3548. https://doi.org/10.1111/jgs.17976

61. Geller HI, Singh A, Alexander KM, Mirto TM, Falk RH. Association Between Ruptured Distal Biceps Tendon and Wild-Type Transthyretin Cardiac Amyloidosis. JAMA. 2017 Sep 12;318(10):962-963. https://doi.org/10.1001/jama.2017.9236

62. Rubin J, Alvarez J, Teruya S, Castano A, Lehman RA, Weidenbaum M, Geller JA, Helmke S, Maurer MS. Hip and knee arthroplasty are common among patients with transthyretin cardiac amyloidosis, occurring years before cardiac amyloid diagnosis: can we identify affected patients earlier? Amyloid. 2017 Dec;24(4):226-230, https://doi.org/10.1080/13506129.2017.1375908

63. Merlini G, Dispenzieri A, Sanchorawala V, Schönland SO, Palladini G, Hawkins PN, Gertz MA. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018 Oct 25;4(1):38. https://doi.org/10.1038/s41572-018-0034-3

64. Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016 Jun 25;387(10038):2641-2654. https://doi.org/10.1016/S0140-6736(15)01274-X

65. Stoopler ET, Alawi F, Laudenbach JM, Sollecito TP. Bullous amyloidosis of the oral cavity: a rare clinical presentation and review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Jun;101(6):734-40. https://doi.org/10.1016/j.tripleo.2006.01.003

66. Рехтина И.Г., Хышова В.А., Зозуля Н.И., Двирнык В.Н., Менделеева Л.П. Нарушения гемостаза у пациентов с системным AL-амилоидозом. Терапевтический архив. 2023;95(9):746-750. https://doi.org/10.26442/00403660,2023.09.202372

67. Dember LM. Amyloidosis-associated kidney disease. J Am Soc Nephrol. 2006 Dec;17(12):3458-71. https://doi.org/10.1681/ASN.2006050460

68. Sharma A, Bansal S, Jain R. Unique morphology of intratubular light chain casts in multiple myeloma: the amyloid cast nephropathy. Indian J Pathol Microbiol. 2014 Oct-Dec;57(4):629-31. https://doi.org/10.4103/0377-4929.142712

69. Gertz MA, Comenzo R, Falk RH et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Am J Hematol 2005; 79(4):319-328. https://doi.org/10.1002/ajh.20381

70. Насонова С.Н., Жиров И.В., Шошина А.А., Осмоловская Ю.Ф., Аншелес А.А., Чайковская О.Я., Добровольская С.В., Сергиенко В.Б., Саидова М.А., Терещенко С.Н., Бойцов С.А. Экспертный центр по амилоидозу сердца: реалии и перспективы. Терапевтический архив 2024;96(4):321-329. https://doi.org/10.26442/00403660.2024.04.202677

71. Takashio S, Yamamuro M, Izumiya Y, Hirakawa K, Marume K, Yamamoto M, Ueda M, Yamashita T, Ishibashi-Ueda H, Yasuda S, Ogawa H, Ando Y, Anzai T, Tsujita K. Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis. ESC Heart Fail. 2018 Feb;5(1):27-35. https://doi.org/10.1002/ehf2.12203

72. Zhang Y, Chaolu H. Diagnostic Role of NT-proBNP in Patients with Cardiac Amyloidosis Involvement: A Meta-Analysis. Arq Bras Cardiol. 2022 Aug;119(2):212-222. English, Portuguese. https://doi.org/10.36660/abc.20210486

73. Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, Klarich KW, Miller WL, Maleszewski JJ, Dispenzieri A. Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. J Am Coll Cardiol. 2016 Sep 6;68(10):1014-20. https://doi.org/10.1016/j.jacc.2016.06.033

74. Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, Quarta CC, Rezk T, Whelan CJ, Gonzalez-Lopez E, Lane T, Gilbertson JA, Rowczenio D, Petrie A, Hawkins PN. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018 Aug 7;39(30):2799-2806. https://doi.org/10.1093/eurheartj/ehx589

75. Adams D., Suhr O.B., Hund E. et al. First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol 2016;29(1):S14–26. PMID: 26734952. https://doi.org/10.1097/wco.0000000000000289

76. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, Greipp PR, Witzig TE, Lust JA, Rajkumar SV, Fonseca R, Zeldenrust SR, McGregor CG, Jaffe AS. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004 Sep 15;22(18):3751-7. https://doi.org/10.1200/JCO.2004.03.029

77. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, Laumann K, Zeldenrust SR, Leung N, Dingli D, Greipp PR, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, Gertz MA. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012 Mar 20;30(9):989-95. https://doi.org/10.1200/JCO.2011.38.5724

78. Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, Bezzina CR, Biagini E, Blom NA, de Boer RA, De Winter T, Elliott PM, Flather M, Garcia-Pavia P, Haugaa KH, Ingles J, Jurcut RO, Klaassen S, Limongelli G, Loeys B, Mogensen J, Olivotto I, Pantazis A, Sharma S, Van Tintelen JP, Ware JS, Kaski JP; ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023 Oct 1;44(37):3503-3626. PMID: 37622657. https://doi.org/10.1093/eurheartj/ehad194

79. Cipriani A, De Michieli L, Porcari A, Licchelli L, Sinigiani G, Tini G, Zampieri M, Sessarego E, Argirò A, Fumagalli C, De Gaspari M, Licordari R, Russo D, Di Bella G, Perfetto F, Autore C, Musumeci B, Canepa M, Merlo M, Sinagra G, Gregori D, Iliceto S, Perazzolo Marra M, Cappelli F, Rapezzi C. Low QRS Voltages in Cardiac Amyloidosis: Clinical Correlates and Prognostic Value. JACC CardioOncol. 2022 Sep 7;4(4):458-470, https://doi.org/10.1016/j.jaccao.2022.08.007

80. Cyrille NB, Goldsmith J, Alvarez J, Maurer MS. Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis. Am J Cardiol. 2014 Oct 1;114(7):108993. https://doi.org/10.1016/j.amjcard.2014.07.026

81. Murtagh B, Hammill SC, Gertz MA, Kyle RA, Tajik AJ, Grogan M. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol. 2005 Feb 15;95(4):535-7. https://doi.org/10.1016/j.amjcard.2004.10.028

82. Cuddy SAM, Chetrit M, Jankowski M, Desai M, Falk RH, Weiner RB, Klein AL, Phelan D, Grogan M. Practical Points for Echocardiography in Cardiac Amyloidosis. J Am SocEchocardiogr. 2022 Sep;35(9):A31-A40. PMID: 36064258. https://doi.org/10.1016/j.echo.2022.06.006

83. Elena Arbelo, Alexandros Protonotarios, Juan R Gimeno, Eloisa Arbustini, Roberto Barriales-Villa, Cristina Basso, Connie R Bezzina, Elena Biagini, Nico A Blom, Rudolf A de Boer, Tim De Winter, Perry M Elliott, Marcus Flather, Pablo Garcia-Pavia, Kristina H Haugaa, Jodie Ingles, RuxandraOanaJurcut, Sabine Klaassen, Giuseppe Limongelli, Bart Loeys, Jens Mogensen, IacopoOlivotto, AntonisPantazis, Sanjay Sharma, J Peter Van Tintelen, James S Ware, Juan Pablo Kaski, ESC Scientific Document Group, 2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC), European Heart Journal, Volume 44, Issue 37, 1 October 2023, Pages 3503-3626. https://doi.org/10.1093/eurheartj/ehad194

84. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, Dubourg O, Kühl U, Maisch B, McKenna WJ, Monserrat L, Pankuweit S, Rapezzi C, Seferovic P, Tavazzi L, Keren A. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008 Jan;29(2):270-6. https://doi.org/10.1093/eurheartj/ehm342

85. Благова О.В. и др. Болезни миокарда и перикарда: от синдромов к диагнозу и лечению/ [идр.]. — М.: ГЭОТАР-Медиа, 2019:753-771. ISBN: 978-5-9704-4743-7 [Blagova O.V. et al. Diseases of the myocardium and pericardium: from syndromes to diagnosis and treatment. — M.:GEOTAR-Media, 2019:753-771 (In Russ.) ISBN: 978-5-9704-4743-7]

86. Rapezzi C, Aimo A, Barison A, Emdin M, Porcari A, Linhart A, Keren A, Merlo M, Sinagra G. Restrictive cardiomyopathy: definition and diagnosis. EurHeartJ. 2022 Dec 1;43(45):4679-4693. https://doi.org/10.1093/eurheartj/ehac543

87. Writing Committee; Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RK, Clarke JO, Dember LM, Frantz JG, Hershberger RE, Maurer MS, Nativi-Nicolau J, Sanchorawala V, Sheikh FH. 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023 Mar 21;81(11):1076-1126. https://doi.org/10.1016/j.jacc.2022.11.022. Epub 2023 Jan 23. Erratum in: J Am Coll Cardiol. 2023 Mar 21;81(11):1135. https://doi.org/10.1016/j.jacc.2023.02.013

88. Dorbala, S., et al. (2021). "ASNC/AHA/ASE/EANM/HFSA/ISA/ SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2— Evidence Base and Standardized Methods of Imaging." Circulation: Cardiovascular Imaging 14(7):e000029. https://doi.org/10.1161/hci.0000000000000029

89. Damy T, Maurer MS, Rapezzi C, Planté-Bordeneuve V, Karayal ON, Mundayat R, Suhr OB, Kristen AV. Clinical, ECG and echocardiographic clues to the diagnosis of TTR-related cardiomyopathy. Open Heart. 2016 Feb 8;3(1):e000289. PMID: 26870387; PMCID: PMC4746524. https://doi.org/10.1136/openhrt-2015-000289

90. Rahman JE, Helou EF, Gelzer-Bell R, Thompson RE, Kuo C, Rodriguez ER, et al. Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. J Am CollCardiol. 2004;43:410-5. https://doi.org/10.1016/j.jacc.2003.08.043

91. Phelan D, Collier P, Thavendiranathan P, Popović ZB, Hanna M, Plana JC, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart 2012;98:1442-8. https://doi.org/10.1136/heartjnl-2012-302353

92. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am SocEchocardiogr. 2015 Jan;28(1):1-39.e14. PMID: 25559473. https://doi.org/10.1016/j.echo.2014.10.003

93. Mitchell C, Rahko PS, Blauwet LA, Canaday B, Finstuen JA, Foster MC, Horton K, Ogunyankin KO, Palma RA, Velazquez EJ. Guidelines for Performing a Comprehensive Transthoracic Echocardiographic Examination in Adults: Recommendations from the American Society of Echocardiography. J Am SocEchocardiogr. 2019 Jan;32(1):1-64. Epub 2018 Oct 1. PMID: 30282592. https://doi.org/10.1016/j.echo.2018.06.004

94. Pagourelias ED, Mirea O, Duchenne J, Van Cleemput J, Delforge M, Bogaert J, Kuznetsova T, Voigt JU. Echo Parameters for Differential Diagnosis in Cardiac Amyloidosis: A Head-to-Head Comparison of Deformation and Nondeformation Parameters. CircCardiovasc Imaging. 2017 Mar;10(3):e005588. PMID: 28298286. https://doi.org/10.1161/CIRCIMAGING.116.005588

95. Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, Burazor I, Caforio ALP, Damy T, Eriksson U, Fontana M, Gillmore JD, Gonzalez-Lopez E, Grogan M, Heymans S, Imazio M, Kindermann I, Kristen AV, Maurer MS, Merlini G, Pantazis A, Pankuweit S, Rigopoulos AG, Linhart A. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur J Heart Fail. 2021 Apr;23 (4):512-526. Epub 2021 Apr 7. PMID: 33826207. https://doi.org/10.1002/ejhf.2140

96. Yilmaz, A., Bauersachs, J., Bengel, F. et al. Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK). Clin Res Cardiol. 2021 Apr;110(4):479-506. https://doi.org/10.1007/s00392-020-01799-3

97. Rosa Lillo, Maurizio Pieroni, Antonia Camporeale, Michele Ciabatti, Antonella Lombardo, Massimo Massetti, Francesca Graziani. Echocardiography in Anderson-Fabry Disease. Rev. Cardiovasc. Med. 2022 May 31;23(6):201. https://doi.org/10.31083/j.rcm2306201

98. Nitsche C, Scully PR, Patel KP, Kammerlander AA, Koschutnik M, Dona C, Wollenweber T, Ahmed N, Thornton GD, Kelion AD, Sabharwal N, Newton JD, Ozkor M, Kennon S, Mullen M, Lloyd G, Fontana M, Hawkins PN, Pugliese F, Menezes LJ, Moon JC, Mascherbauer J, Treibel TA. Prevalence and Outcomes of Concomitant Aortic Stenosis and Cardiac Amyloidosis. J Am CollCardiol. 2021 Jan 19;77(2):128-139. Epub 2020 Nov 9. PMID: 33181246; PMCID: PMC7805267. https://doi.org/10.1016/j.jacc.2020,11.006

99. Aimo A, Camerini L, Fabiani I, Morfino P, Panichella G, Barison A, Pucci A, Castiglione V, Vergaro G, Sinagra G, Emdin M. Valvular heart disease in patients with cardiac amyloidosis. Heart Fail Rev. 2024 Jan;29(1):65-77. https://doi.org/10.1007/s10741-023-10350-1

100. Okafor, J.; Khattar, R.; Sharma, R.; Kouranos, V. The Role of Echocardiography in the Contemporary Diagnosis and Prognosis of Cardiac Sarcoidosis: A Comprehensive Review. Life 2023;13:1653. https://doi.org/10.3390/life13081653

101. Kazuhiro TOUHARA, Takamune ACHIHA, Shingo TOYOTA, Shuki OKUHARA, Motohide TAKAHARA, Yuhei HOSHIKUMA, Shuhei YAMADA, Tomoaki MURAKAMI, Maki KOBAYASHI, Haruhiko KISHIMA, Internal Carotid Artery Occlusion Associated with Cardiac Sarcoidosis during the Postpartum Period Treated with Thrombectomy: A Case Report, NMC Case Report Journal. 2025 Apr 11:12:133-138. https://doi.org/10.2176/jns-nmc.2024-0264

102. Javadi N., Bismee N.N., Abbas M.T., Scalia I.G., Pereyra M., Baba Ali N., Attaripour Esfahani S., Awad K., Farina J.M., Ayoub C. et al. Left Atrial Strain: State of the Art and Clinical Implications. J Pers Med . 2024 Nov 5;14(11):1093. https://doi.org/10.3390/jpm14111093

103. Palmiero G, Rubino M, Monda E, Caiazza M, D'Urso L, Carlomagno G, Verrillo F, Ascione R, Manganelli F, Cerciello G, De Rimini ML, Bossone E, Pacileo G, Calabrò P, Golino P, Ascione L, Caso P, Limongelli G. Global Left Ventricular Myocardial Work Efficiency in Heart Failure Patien J CardiovascEchogr. 2021 JulSep;31(3):157-164. Epub 2021 Oct 26. PMID: 34900551; PMCID: PMC8603776. https://doi.org/10.4103/jcecho.jcecho_16_21

104. Clemmensen TS, Eiskjær H, Ladefoged B, Mikkelsen F, Sørensen J, Granstam SO, Rosengren S, Flachskampf FA, Poulsen SH. Prognostic implications of left ventricular myocardial work indices in cardiac amyloidosis. 2021 May 10; 22(6):695-704. PMID: 32529207. https://doi.org/10.1093/ehjci/jeaa097

105. Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, Wechalekar AD, Berk JL, Quarta CC, Grogan M, Lachmann HJ, Bokhari S, Castano A, Dorbala S, Johnson GB, Glaudemans AW, Rezk T, Fontana M, Palladini G, Milani P, Guidalotti PL, Flatman K, Lane T, Vonberg FW, Whelan CJ, Moon JC, Ruberg FL, Miller EJ, Hutt DF, Hazenberg BP, Rapezzi C, Hawkins PN. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016 Jun 14;133(24):2404-12. https://doi.org/10.1161/CIRCULATIONAHA.116.021612

106. Томография сердца/ под ред. С.К. Тернового. – М.: ГЭОТАР-Медиа, 2018.–296 с. ISBN: 978-5-9704-4608-9 [Tomography of the heart / ed. S.K. Ternovy. – M.: GEOTAR-Media, 2018.–296 p. ISBN: 978-5-9704-4608-9]

107. Fontana M, Martinez-Naharro A, Chacko L, Rowczenio D, Gilbertson JA, Whelan CJ, Strehina S, Lane T, Moon J, Hutt DF, Kellman P, Petrie A, Hawkins PN, Gillmore JD. Reduction in CMR Derived Extracellular Volume With Patisiran Indicates Cardiac Amyloid Regression. JACC Cardiovasc Imaging. 2021 Jan;14(1):189-199. https://doi.org/10.1016/j.jcmg.2020.07.043

108. Maggialetti N., Torrente A., Lorusso G., et al. Role of Cardiovascular Magnetic Resonance in Cardiac Amyloidosis: A Narrative Review. J Pers Med. 2024;14(4):407. https://doi.org/10.3390/jpm14040407

109. Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Banypersad SM, Maestrini V, Barcella W, Rosmini S, Bulluck H, Sayed RH, Patel K, Mamhood S, Bucciarelli-Ducci C, Whelan CJ, Herrey AS, Lachmann HJ, Wechalekar AD, Manisty CH, Schelbert EB, Kellman P, Gillmore JD, Hawkins PN, Moon JC. Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation. 2015 Oct 20;132(16):1570-9. https://doi.org/10.1161/CIRCULATIONAHA.115.016567

110. Cai S, Haghbayan H, Chan KKW, Deva DP, Jimenez-Juan L, Connelly KA, Ng MY, Yan RT, Yan AT. Tissue mapping by cardiac magnetic resonance imaging for the prognostication of cardiac amyloidosis: A systematic review and meta-analysis. Int J Cardiol. 2024 May 15;403:131892. https://doi.org/10.1016/j.ijcard.2024.131892

111. Martinez-Naharro A, Patel R, Kotecha T, Karia N, Ioannou A, Petrie A, Chacko LA, Razvi Y, Ravichandran S, Brown J, Law S, Quarta C, Mahmood S, Wisniowski B, Pica S, Sachchithanantham S, Lachmann HJ, Moon JC, Knight DS, Whelan C, Venneri L, Xue H, Kellman P, Gillmore JD, Hawkins PN, Wechalekar AD, Fontana M. Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment. Eur Heart J. 2022 Dec 1;43(45):4722-4735. https://doi.org/10.1093/eurheartj/ehac363

112. Pan JA, Kerwin MJ, Salerno M. Native T1 Mapping, Extracellular Volume Mapping, and Late Gadolinium Enhancement in Cardiac Amyloidosis: A Meta-Analysis. JACC Cardiovasc Imaging. 2020 Jun;13(6):1299-1310. https://doi.org/10.1016/j.jcmg.2020.03.010

113. Karamitsos TD, Piechnik SK, Banypersad SM, Fontana M, Ntusi NB, Ferreira VM, Whelan CJ, Myerson SG, Robson MD, Hawkins PN, Neubauer S, Moon JC. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging. 2013 Apr;6(4):48897. https://doi.org/10.1016/j.jcmg.2012.11.013

114. Lavall D, Vosshage NH, Geßner R, Stöbe S, Ebel S, Denecke T, Hagendorff A, Laufs U. Native T1 mapping for the diagnosis of cardiac amyloidosis in patients with left ventricular hypertrophy. Clin Res Cardiol. 2023 Mar;112(3):334-342. https://doi.org/10.1007/s00392-022-02005-2

115. Martinez-Naharro A, Patel R, Kotecha T, Karia N, Ioannou A, Petrie A, Chacko LA, Razvi Y, Ravichandran S, Brown J, Law S, Quarta C, Mahmood S, Wisniowski B, Pica S, Sachchithanantham S, Lachmann HJ, Moon JC, Knight DS, Whelan C, Venneri L, Xue H, Kellman P, Gillmore JD, Hawkins PN, Wechalekar AD, Fontana M. Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment. Eur Heart J. 2022 Dec 1;43(45):4722-4735. https://doi.org/10.1093/eurheartj/ehac363

116. Martinez-Naharro A, Baksi AJ, Hawkins PN, Fontana M. Diagnostic imaging of cardiac amyloidosis. Nat Rev Cardiol. 2020 Jul;17(7):413-426. https://doi.org/10.1038/s41569-020-0334-7

117. Ridouani F, Damy T, Tacher V, Derbel H, Legou F, Sifaoui I, Audureau E, Bodez D, Rahmouni A, Deux JF. Myocardial native T2 measurement to differentiate light-chain and transthyretin cardiac amyloidosis and assess prognosis. J Cardiovasc Magn Reson. 2018 Aug 16;20(1):58. https://doi.org/10.1186/s12968-018-0478-3

118. Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, Salvi F, Ciliberti P, Pastorelli F, Biagini E, Coccolo F, Cooke RM, BacchiReggiani L, Sangiorgi D, Ferlini A, Cavo M, Zamagni E, Fonte ML, Palladini G, Salinaro F, Musca F, Obici L, Branzi A, Perlini S. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009 Sep 29;120(13):1203-12. https://doi.org/10.1161/CIRCULATIONAHA.108.843334

119. Yilmaz A, Bauersachs J, Bengel F, Büchel R, Kindermann I, Klingel K, et al. Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK). Clin Res Cardiol. 2021;110(4):479-506.doi.org/10,1007/s00392-020-01799-3

120. Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, Nair AP, Nativi-Nicolau J, Ruberg FL; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation. 2020 Jul 7;142(1):e7e22. https://doi.org/10.1161/CIR.0000000000000792. Epub 2020 Jun 1. Erratum in: Circulation. 2021 Jul 6;144(1):e10, https://doi.org/10.1161/CIR.0000000000000997. Erratum in: Circulation. 2021 Jul 6;144(1):e11. https://doi.org/10.1161/CIR.0000000000000998

121. Benson MD, Buxbaum JN, Eisenberg DS, Merlini G, Saraiva MJM, Sekijima Y, et al. Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid. 2018;25(4):215–9. https://doi.org/10.1080/13506129.2018.1549825

122. Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: A population-based autopsy study. Ann Med. 2008;40(3):2329. https://doi.org/10.1080/07853890701842988

123. Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2—Diagnostic criteria and appropriate utilization. J Nucl Cardiol. 2019; Available from: https://doi.org/10.1007/s12350-019-01761-5

124. Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019 Jun 11;73(22):2872-2891. https://doi.org/10.1016/j.jacc.2019.04.003

125. Park GY, Jamerlan A, Shim KH, An SSA. Diagnostic and Treatment Approaches Involving Transthyretin in Amyloidogenic Diseases. Int J Mol Sci. 2019 Jun 18;20(12):2982. https://doi.org/10.3390/ijms20122982.

126. Conceição I, González-Duarte A, Obici L, Schmidt HH, Simoneau D, Ong ML, Amass L. "Red-flag" symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst. 2016 Mar;21(1):5-9. https://doi.org/10.1111/jns.12153

127. Devigili G, Tugnoli V, Penza P, Camozzi F, Lombardi R, Melli G, Broglio L, Granieri E, Lauria G. The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain. 2008 Jul;131(Pt 7):1912-25. https://doi.org/10.1093/brain/awn093. Epub 2008 Jun 4. PMID: 18524793; PMCID: PMC2442424

128. Lobato L, Beirão I, Silva M, Bravo F, Silvestre F, Guimarães S, Sousa A, Noël LH, Sequeiros J. Familial ATTR amyloidosis: microalbuminuria as a predictor of symptomatic disease and clinical nephropathy. Nephrol Dial Transplant. 2003 Mar;18(3):5328. https://doi.org/10.1093/ndt/18.3.532.

129. Papagianni A, Ihne S, Zeller D, Morbach C, Üçeyler N, Sommer C. Clinical and apparative investigation of large and small nerve fiber impairment in mixed cohort of ATTR-amyloidosis: impact on patient management and new insights in wild-type. Amyloid. 2022 Mar;29(1):14-22. https://doi.org/10.1080/13506129.2021.1976751 . Epub 2021 Oct 11. PMID: 34632904.

130. Sakashita N, Ando Y, Jinnouchi K, Yoshimatsu M, Terazaki H, Obayashi K, Takeya M. Familial amyloidotic polyneuropathy (ATTR Val30Met) with widespread cerebral amyloid angiopathy and lethal cerebral hemorrhage. Pathol Int. 2001 Jun;51(6):476-80, https://doi.org/10.1046/j.1440-1827.2001.01228.x.

131. Ikeda SI. [Cerebral amyloid angiopathy with familial transthyretinderived oculoleptomeningeal amyloidosis]. Brain Nerve. 2013 Jul;65(7):831-42. Japanese.

132. Golbus JR, Wells JM, Dickinson MG, Hummel SL. Importance of Genetic Testing in the Diagnosis of Transthyretin Cardiac Amyloidosis. Am J Med. 2018;131(7):e303-4. https://doi.org/10.1016/j.amjmed.2018.02.005

133. Obici L, Kuks JB, Buades J, Adams D, Suhr OB, Coelho T, et al. Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis. Curr Opin Neurol. 2016;29:S27–35. https://doi.org/10.1097/wco.0000000000000290

134. Hutt DF, Quigley AM, Page J, Hall ML, Burniston M, Gopaul D, et al. Utility and limitations of 3,3-diphosphono-1, 2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur Heart J Cardiovasc Imaging. 2014;15(11):1289-98. https://doi.org/10.1093/ehjci/jeu107

135. Резник Е.В., Нгуен Т.Л., Степанова Е.А., Устюжанин Д.В., Никитин И.Г. Амилоидоз сердца: взгляд терапевта и кардиолога. Архивъ внутренней медицины. 2020;10(6):430-457. https://doi.org/10.20514/2226-6704-2020-10-6-430-457

136. Poterucha TJ, Elias P, Bokhari S, Einstein AJ, DeLuca A, Kinkhabwala M, et al. Diagnosing Transthyretin Cardiac Amyloidosis by Technetium Tc 99m Pyrophosphate: A Test in Evolution. JACC Cardiovasc Imaging. 2021;14(6):1221–1231. https://doi.org/10.1016/j.jcmg.2020.08.027

137. Gertz M, Adams D, Ando Y, Beirão JM, Bokhari S, Coelho T, et al. Avoiding misdiagnosis: Expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. BMC Fam Pract. 2020;21(1):1-12. https://doi.org/10.1186/s12875-020-01252-4

138. Sprangers B, Claes K, Evenepoel P, Kuypers D, Poesen K, Delforge M, et al. Comparison of 2 Serum-Free Light-Chain Assays in CKD Patients. Kidney Int Reports. 2020;5(5):627–31. Available from: https://doi.org/10.1016/j.ekir.2020.01.019

139. Bonderman D, Pölzl G, Ablasser K, Agis H, Aschauer S, AuerGrumbach M, et al. Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement. Wien Klin Wochenschr. 2020;132(23–24):742–761. https://doi.org/10.1007/s00508-020-01781-z

140. Dispenzieri A, Kyle R, Merlini G et al. International myeloma working group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009; 23:215-224. https://doi.org/10.1038/leu.2008.307

141. Rahel S, Flammer Andreas J, Sabine G et al. Expert recommendation from the swiss amyloidosis network (SAN) for systemic ALamyloidosis. Swiss Med Wkly . 2020 Dec 5:150:w20364. https://doi.org/10.4414/smw.2020.20364

142. Quarta, CC, Gonzalez-Lopez E, Gilbertson JA., et al. Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis. Eur Heart J 2017;38(24):1905-1908. https://doi.org/10.1093/eurheartj/ehx047

143. Kimmich C, Schönland S, Kräker S et al. Amyloid in bone marrow smears in systemic light-chain amyloidosis. Amyloid 2017; 24(1):52-59. https://doi.org/10.1080/13506129.2017.1314959

144. Muchtar E, Dispenzieri A, Lacy MQ et al. Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. Ann Med 2017; 49(7):545-551. https://doi.org/10.1080/07853890.2017.1304649

145. Gertz MA, Comenzo R, Falk RH et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Am J Hematol 2005; 79(4):319-328. https://doi.org/10.1002/ajh.20381

146. Phull P, Sanchorawala V, Connors LH et al. Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR). Amyloid 2018; 25(1):62-67. https://doi.org/10.1080/13506129.2018.1436048

147. Coelho T, Merlini G, Bulawa CE, Fleming JA, Judge DP, Kelly JW, Maurer MS, Planté-Bordeneuve V, Labaudinière R, Mundayat R, Riley S, Lombardo I, Huertas P. Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis. Neurol Ther. 2016 Jun;5(1):1-25. https://doi.org/10.1007/s40120-016-0040-х

148. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018;379(11):1007–16. https://doi.org/10.1056/NEJMoa1805689

149. Hanna M, Damy T, Grogan M, Stewart M, Gundapaneni B, Patterson TA, et al. Impact of Tafamidis on Health-Related Quality of Life in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial). Am J Cardiol. 2021;141:98–105. https://doi.org/10.1016/j.amjcard.2020.10.066

150. Badr Eslam R, Öztürk B, Rettl R, Capelle CDJ, Qin H, Binder C, et al. Impact of Tafamidis and Optimal Background Treatment on Physical Performance in Patients With Transthyretin Amyloid Cardiomyopathy. Circ Heart Fail. 2022;15(7):e008381. https://doi.org/10.1161/CIRCHEARTFAILURE.121.008381

151. Elliott P, Drachman BM, Gottlieb SS, Hoffman JE, Hummel SL, Lenihan DJ, Ebede B, Gundapaneni B, Li B, Sultan MB, Shah SJ. Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy. Circ Heart Fail. 2022 Jan;15(1):e008193. https://doi.org/10.1161/circheartfailure.120.008193

152. Damy T, Garcia-Pavia P, Hanna M, Judge DP, Merlini G, Gundapaneni B, et al. Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and longterm extension study. Eur J Heart Fail. 2021;23(2):277-85. https:// doi.org/10.1002/ejhf.2027

153. Шошина А.А., Аншелес А.А., Насонова С.Н., Жиров И.В., Сергиенко В.Б., Терещенко С. Н. Роль сцинтиграфии миокарда с 99mTc-пирофосфатом в оценке эффективности терапии тафамидисом на примере серии клинических случаев. Российский кардиологический журнал. 2025;30(1):6200. https://doi.org/10.15829/1560-4071-2025-6200

154. Gillmore JD, Judge DP, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs S, Grogan M, Hanna M, Hoffman J, Masri A, et al. ; ATTRibute-CM Investigators. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med. 2024;390:132-142. https://doi.org/10.1056/NEJMoa2305434

155. Judge DP, Gillmore JD, Alexander KM, Ambardekar AV, Cappelli F, Fontana M, García-Pavía P, Grodin JL, Grogan M, Hanna M, Masri A, Nativi-Nicolau J, Obici L, Hvitfeldt Poulsen S, Sarswat N, Shah K, Soman P, Lystig T, Cao X, Wang K, Pecoraro ML, Tamby JF, Katz L, Sinha U, Fox JC, Maurer MS. Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial. Circulation. 2025 Mar 4;151(9):601-611. https://doi.org/10.1161/CIRCULATIONAHA.124.072771

156. Razvi Y, Judge DP, Martinez-Naharro A, Ioannou A, Venneri L, Patel R, Gillmore JD, Kellman P, Edwards L, Taubel J, Du J, Tamby JF, Castaño A, Siddhanti S, Katz L, Fox JC, Fontana M. Effect of Acoramidis on Myocardial Structure and Function in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Cardiac Magnetic Resonance (CMR) Substudy. Circ Heart Fail. 2024 Dec;17(12):e012135. https://doi.org/10.1161/CIRCHEARTFAILURE.124.012135

157. Coelho T, Adams D, Silva A, Lozeron P, Hawkins PN, Mant T, Perez J, Chiesa J, Warrington S, Tranter E, Munisamy M, Falzone R, Harrop J, Cehelsky J, Bettencourt BR, Geissler M, Butler JS, Sehgal A, Meyers RE, Chen Q, Borland T, Hutabarat RM, Clausen VA, Alvarez R, Fitzgerald K, Gamba-Vitalo C, Nochur SV, Vaishnaw AK, Sah DW, Gollob JA, Suhr OB. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013 Aug 29;369(9):81929. https://doi.org/10.1056/NEJMoa1208760

158. Adams D, Gonzalez-Duarte A, O'Riordan WD, Yang CC, Ueda M, Kristen AV, Tournev I, Schmidt HH, Coelho T, Berk JL, Lin KP, Vita G, Attarian S, Planté-Bordeneuve V, Mezei MM, Campistol JM, Buades J, Brannagan TH 3rd, Kim BJ, Oh J, Parman Y, Sekijima Y, Hawkins PN, Solomon SD, Polydefkis M, Dyck PJ, Gandhi PJ, Goyal S, Chen J, Strahs AL, Nochur SV, Sweetser MT, Garg PP, Vaishnaw AK, Gollob JA, Suhr OB. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018 Jul 5;379(1):11-21. https://doi.org/10.1056/NEJMoa1716153

159. Solomon SD, Adams D, Kristen A, Grogan M, González-Duarte A, Maurer MS, Merlini G, Damy T, Slama MS, Brannagan TH 3rd, Dispenzieri A, Berk JL, Shah AM, Garg P, Vaishnaw A, Karsten V, Chen J, Gollob J, Vest J, Suhr O. Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis. Circulation. 2019 Jan 22;139(4):431-443. https://doi.org/10.1161/CIRCULATIONAHA.118.035831

160. Maurer MS, Kale P, Fontana M, Berk JL, Grogan M, Gustafsson F, Hung RR, Gottlieb RL, Damy T, González-Duarte A, Sarswat N, Sekijima Y, Tahara N, Taylor MS, Kubanek M, Donal E, Palecek T, Tsujita K, Tang WHW, Yu WC, Obici L, Simões M, Fernandes F, Poulsen SH, Diemberger I, Perfetto F, Solomon SD, Di Carli M, Badri P, White MT, Chen J, Yureneva E, Sweetser MT, Jay PY, Garg PP, Vest J, Gillmore JD; APOLLO-B Trial Investigators. Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis. N Engl J Med. 2023 Oct 26;389(17):1553-1565. PMID: 37888916. PMCID: PMC10757426. https://doi.org/10.1056/NEJMoa2300757

161. Adams D, Tournev IL, Taylor MS, Coelho T, Planté-Bordeneuve V, Berk JL, González-Duarte A, Gillmore JD, Low SC, Sekijima Y, Obici L, Chen C, Badri P, Arum SM, Vest J, Polydefkis M; HELIOS-A Collaborators. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid. 2023 Mar;30(1):1-9. https://doi.org/10.1080/13506129.2022.2091985

162. Garcia-Pavia P, Grogan M, Kale P, Berk JL, Maurer MS, Conceição I, Di Carli M, Solomon SD, Chen C, Yureneva E, Vest J, Gillmore JD. Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy. Eur J Heart Fail. 2024 Feb;26(2):397-410. https://doi.org/10.1002/ejhf.3138

163. Fontana M, Berk JL, Gillmore JD, Witteles RM, Grogan M, Drachman B, Damy T, Garcia-Pavia P, Taubel J, Solomon SD, Sheikh FH, Tahara N, González-Costello J, Tsujita K, Morbach C, Pozsonyi Z, Petrie MC, Delgado D, Van der Meer P, Jabbour A, Bondue A, Kim D, Azevedo O, Hvitfeldt Poulsen S, Yilmaz A, Jankowska EA, Algalarrondo V, Slugg A, Garg PP, Boyle KL, Yureneva E, Silliman N, Yang L, Chen J, Eraly SA, Vest J, Maurer MS; HELIOS-B Trial Investigators. Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy. N Engl J Med. 2025 Jan 2;392(1):33-44. https://doi.org/10.1056/NEJMoa2409134

164. Witteles RM, Garcia-Pavia P, Damy T, Grogan M, Sheikh FH, Morbach C, Bender S, Exter J, Eraly SA, Fontana M. Vutrisiran Improves Survival and Reduces Cardiovascular Events in ATTR Amyloid Cardiomyopathy: HELIOS-B. J Am Coll Cardiol. 2025 Apr 30:S0735-1097(25)06170-4. https://doi.org/10.1016/j.jacc.2025.04.008

165. Coelho T, Marques W Jr, Dasgupta NR, Chao CC, Parman Y, França MC Jr, Guo YC, Wixner J, Ro LS, Calandra CR, Kowacs PA, Berk JL, Obici L, Barroso FA, Weiler M, Conceição I, Jung SW, Buchele G, Brambatti M, Chen J, Hughes SG, Schneider E, Viney NJ, Masri A, Gertz MR, Ando Y, Gillmore JD, Khella S, Dyck PJB, Waddington Cruz M; NEURO-TTRansform Investigators. Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy. JAMA. 2023 Oct 17;330(15):1448-1458. https://doi.org/10.1001/jama.2023.18688

166. Masri A, Maurer MS, Claggett BL, Kulac I, Waddington Cruz M, Conceição I, Weiler M, Berk JL, Gertz M, Gillmore JD, Rush S, Chen J, Zhou W, Kwoh J, Duran JM, Tsimikas S, Solomon SD. Effect of Eplontersen on Cardiac Structure and Function in Patients With Hereditary Transthyretin Amyloidosis. J Card Fail. 2024 Aug;30(8):973-980, https://doi.org/10.1016/j.cardfail.2023.11.016

167. Brito D, Albrecht FC, de Arenaza DP, Bart N, Better N, Carvajal-Juarez I, Conceição I, Damy T, Dorbala S, Fidalgo JC, Garcia-Pavia P, Ge J, Gillmore JD, Grzybowski J, Obici L, Piñero D, Rapezzi C, Ueda M, Pinto FJ. World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). Glob Heart. 2023 Oct 26;18(1):59. https://doi.org/10.5334/gh.1262

168. Nuvolone M, Nevon A, Merlini G. Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis. BioDrugs. 2022 Sep;36(5):591-608. https://doi.org/10.1007/s40259-022-00550-w

169. Garcia-Pavia P, Aus dem Siepen F, Donal E, Lairez O, van der Meer P, Kristen AV, Mercuri MF, Michalon A, Frost RJA, Grimm J, Nitsch RM, Hock C, Kahr PC, Damy T. Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid. N Engl J Med. 2023 Jul 20;389(3):239-250. https://doi.org/10.1056/NEJMoa2303765

170. Gillmore JD, Gane E, Taubel J, Kao J, Fontana M, Maitland ML, Seitzer J, O'Connell D, Walsh KR, Wood K, Phillips J, Xu Y, Amaral A, Boyd AP, Cehelsky JE, McKee MD, Schiermeier A, Harari O, Murphy A, Kyratsous CA, Zambrowicz B, Soltys R, Gutstein DE, Leonard J, Sepp-Lorenzino L, Lebwohl D. CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. N Engl J Med. 2021 Aug 5;385(6):493-502. https://doi.org/10.1056/NEJMoa2107454

171. Kotit S. Lessons from the first-in-human in vivo CRISPR/Cas9 editing of the TTR gene by NTLA-2001 trial in patients with transthyretin amyloidosis with cardiomyopathy. Glob Cardiol Sci Pract. 2023 Jan 30;2023(1):e202304. https://doi.org/10.21542/gcsp.2023.4

172. Sperry BW, Hanna M, Shah SJ, Jaber WA, Spertus JA. Spironolactone in Patients With an Echocardiographic HFpEF Phenotype Suggestive of Cardiac Amyloidosis: Results From TOPCAT. JACC Heart Fail. 2021 Nov;9(11):795-802. https://doi.org/10.1016/j.jchf.2021.06.007

173. Ioannou A, Massa P, Patel RK, Razvi Y, Porcari A, Rauf MU, Jiang A, Cabras G, Filisetti S, Bolhuis RE, Bandera F, Venneri L, MartinezNaharro A, Law S, Kotecha T, Virsinskaite R, Knight DS, Emdin M, Petrie A, Lachmann H, Wechelakar A, Petrie M, Hughes A, Freemantle N, Hawkins PN, Whelan C, McMurray JJV, Gillmore JD, Fontana M. Conventional heart failure therapy in cardiac ATTR amyloidosis. Eur Heart J. 2023 Aug 14;44(31):2893-2907. https:// doi.org/10.1093/eurheartj/ehad347. Erratum in: Eur Heart J. 2024 Apr 7;45(14):1251. https://doi.org/10.1093/eurheartj/ehae140

174. Dobner S, Bernhard B, Asatryan B, Windecker S, Stortecky S, Pilgrim T, Gräni C, Hunziker L. SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin. ESC Heart Fail. 2023 Feb;10(1):397-404. https://doi.org/10.1002/ehf2.14188

175. Zampieri M, Argirò A, Allinovi M, Perfetto F, Cappelli F. SGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series. Intern Emerg Med. 2022 Jun;17(4):1243-1245. https://doi.org/10.1007/s11739-022-02944-8

176. Lang FM, Teruya S, Weinsaft A, Cuomo M, Santos AM, Nalbandian A, Bampatsias D, Maurer MS. Sodium-glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: Analyses of short-term efficacy and safety. Eur J Heart Fail. 2024 Apr;26(4):938-947. https://doi.org/10.1002/ejhf.3198

177. Porcari A, Cappelli F, Nitsche C, Tomasoni D, Sinigiani G, Longhi S, Bordignon L, Masri A, Serenelli M, Urey M, Musumeci B, Cipriani A, Canepa M, Badr-Eslam R, Kronberger C, Chimenti C, Zampieri M, Allegro V, Razvi Y, Patel R, Ioannou A, Rauf MU, Petrie A, Whelan C, Emdin M, Metra M, Merlo M, Sinagra G, Hawkins PN, Solomon SD, Gillmore JD, Fontana M. SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid Cardiomyopathy. J Am Coll Cardiol. 2024 Jun 18;83(24):2411-2422. https://doi.org/10.1016/j.jacc.2024.03.429

178. Schwegel N, Toferer C, Zach DK, Santner V, Höller V, Lugitsch J, Wallner M, Gollmer J, Aziz F, von Lewinski D, Kolesnik E, Ablasser K, Zirlik A, Sourij H, Verheyen N. Impact of SGLT2-Inhibitor Therapy on Survival in Patients with Transthyretin Amyloid Cardiomyopathy: Analysis of a Prospective Registry Study. J Clin Med. 2024 Oct 8;13(19):5966. https://doi.org/10.3390/jcm13195966

179. Byer SH, Sivamurugan A, Grewal US, Fradley MG, Dominic P. Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Cardiovascular Outcomes in Transthyretin Amyloid Cardiomyopathy. Am J Cardiol. 2025 May 15;243:15-18. https://doi.org/10.1016/j.amjcard.2025.01.012

180. Karakasis P, Theofilis P, Patoulias D, Schuermans A, Vlachakis PK, Klisic A, Rizzo M, Fragakis N. Sodium-glucose cotransporter 2 inhibitors and outcomes in transthyretin amyloid cardiomyopathy: Systematic review and meta-analysis. Eur J Clin Invest. 2025 Jun;55(6):e14392. https://doi.org/10.1111/eci.14392

181. Ioannou A, Massa P, Patel RK, Razvi Y, Porcari A, Rauf MU, Jiang A, Cabras G, Filisetti S, Bolhuis RE, Bandera F, Venneri L, MartinezNaharro A, Law S, Kotecha T, Virsinskaite R, Knight DS, Emdin M, Petrie A, Lachmann H, Wechelakar A, Petrie M, Hughes A, Freemantle N, Hawkins PN, Whelan C, McMurray JJV, Gillmore JD, Fontana M. Conventional heart failure therapy in cardiac ATTR amyloidosis. Eur Heart J. 2023 Aug 14;44(31):2893-2907. https:// doi.org/10.1093/eurheartj/ehad347. Erratum in: Eur Heart J. 2024 Apr 7;45(14):1251. https://doi.org/10.1093/eurheartj/ehae140

182. Briasoulis A, Stamatelopoulos K, Petropoulos I, Patras R, Theodorakakou F, Gavriatopoulou M, Ntalianis A, Dimopoulos MA, Kastritis E. Utilization and tolerance of beta-blockers among patients with AL amyloidosis. Amyloid. 2022 Mar;29(1):31-37. https://doi.org/10.1080/13506129.2021.1981281

183. Kwok CS, Choy CH, Pinney J, Townend JN, Whelan C, Fontana M, Gillmore JD, Steeds RP, Moody WE. Effect of beta-blockade on mortality in patients with cardiac amyloidosis: A systematic review and meta-analysis. ESC Heart Fail. 2024 Dec;11(6):3901-3910, https://doi.org/10.1002/ehf2.14975

184. Kang Y, Qu N, Zhang Z, Zhang Q, Chen X, Fu M. Tolerability and effectiveness of beta-blockers in patients with cardiac amyloidosis: A systematic review and meta-analysis. Int J Cardiol. 2024 May 1;402:131813. https://doi.org/10.1016/j.ijcard.2024.131813

185. Aus dem Siepen F, Hein S, Bauer R, Katus HA, Kristen AV. Standard heart failure medication in cardiac transthyretin amyloidosis: useful or harmful? Amyloid. 2017 Mar;24(sup1):132-133. https://doi.org/10.1080/13506129.2016.1272453

186. Aus dem Siepen F, Hein S, Hofmann E, Nagel C, Schwarting SK, Hegenbart U, Schönland SO, Weiler M, Frey N, Kristen AV. Prognostic Value of Standard Heart Failure Medication in Patients with Cardiac Transthyretin Amyloidosis. J Clin Med. 2024 Apr 12;13(8):2257. https://doi.org/10.3390/jcm13082257

187. Bukhari S, Khan SZ, Bashir Z. Atrial Fibrillation, Thromboembolic Risk, and Anticoagulation in Cardiac Amyloidosis: A Review. J Card Fail. 2023 Jan;29(1):76-86. https://doi.org/10.1016/j.cardfail.2022.08.008

188. Vilches S, Fontana M, Gonzalez-Lopez E, Mitrani L, Saturi G, Renju M, Griffin JM, Caponetti A, Gnanasampanthan S, De Los Santos J, Gagliardi C, Rivas A, Dominguez F, Longhi S, Rapezzi C, Maurer MS, Gillmore J, Garcia-Pavia P. Systemic embolism in amyloid transthyretin cardiomyopathy. Eur J Heart Fail. 2022 Aug;24(8):1387-1396. https://doi.org/10.1002/ejhf.2566

189. Nicol M, Siguret V, Vergaro G, Aimo A, Emdin M, Dillinger JG, Baudet M, Cohen-Solal A, Villesuzanne C, Harel S, Royer B, Arnulf B, Logeart D. Thromboembolism and bleeding in systemic amyloidosis: a review. ESC Heart Fail. 2022 Feb;9(1):11-20. https:/ doi.org/10.1002/ehf2.13701

190. Vilches S, Fontana M, Gonzalez-Lopez E, Mitrani L, Saturi G, Renju M, Griffin JM, Caponetti A, Gnanasampanthan S, De Los Santos J, Gagliardi C, Rivas A, Dominguez F, Longhi S, Rapezzi C, Maurer MS, Gillmore J, Garcia-Pavia P. Systemic embolism in amyloid transthyretin cardiomyopathy. Eur J Heart Fail. 2022 Aug;24(8):1387-1396. https://doi.org/10.1002/ejhf.2566

191. Barbhaiya CR, Kumar S, Baldinger SH, Michaud GF, Stevenson WG, Falk R, John RM. Electrophysiologic assessment of conduction abnormalities and atrial arrhythmias associated with amyloid cardiomyopathy. Heart Rhythm. 2016 Feb;13(2):383-90. https:// doi.org/10.1016/j.hrthm.2015.09.016

192. Donnelly JP, Sperry BW, Gabrovsek A, Ikram A, Tang WHW, Estep J, Hanna M. Digoxin Use in Cardiac Amyloidosis. Am J Cardiol. 2020 Oct 15;133:134-138. https://doi.org/10.1016/j.amjcard.2020,07.034

193. Kristen AV, Dengler TJ, Hegenbart U, Schonland SO, Goldschmidt H, Sack FU, Voss F, Becker R, Katus HA, Bauer A. Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm. 2008 Feb;5(2):235-40. https://doi.org/10.1016/j.hrthm.2007.10.016

194. Клинические рекомендации МЗ РФ «Брадиаритмии и нарушения проводимости» 2025 г. https://cr.minzdrav.gov.ru/viewcr/160_2

195. Ando Y, Adams D, Benson MD, et al. Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis. Amyloid. 2022;29(3):143-155. https://doi.org/10.1080/13506129.2022.2052838

196. Masri A, Maurer MS, Claggett BL, et al. Effect of Eplontersen on Cardiac Structure and Function in Patients With Hereditary Transthyretin Amyloidosis. J Card Fail. 2024;30(8):973-980. https://doi.org/10.1016/j.cardfail.2023.11.016

197. Hoss S, Habib M, Silver J, et al. Genetic Testing for Diagnosis of Hypertrophic Cardiomyopathy Mimics: Yield and Clinical Significance. Circ Genom Precis Med. 2020;13(2):e002748. https://doi.org/10.1161/CIRCGEN.119.002748

198. Hagège A, Puscas T, El Hachmi M, et al. The French hypertrophic cardiomyopathy gene register: A systematic large gene screening for hypertrophic cardiomyopathy. Int J Cardiol. 2024;417:132542. https://doi.org/10.1016/j.ijcard.2024.132542

199. Cruccu G, Sommer C, Anand P, et al. EFNS guidelines on neuropathic pain assessment: revised 2009. Eur J Neurol. 2010;17(8):1010-1018. https://doi.org/10.1111/j.1468-1331.2010,02969.x

200. Kroenke K, Krebs EE, Bair MJ. Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews. Gen Hosp Psychiatry. 2009;31(3):206-219. https://doi.org/10.1016/j.genhosppsych.2008.12.006

201. Barge-Caballero G, Barge-Caballero E, López-Pérez M, BilbaoQuesada R, González-Babarro E, Gómez-Otero I, López-López A, Gutiérrez-Feijoo M, Varela-Román A, González-Juanatey C, DíazCastro Ó, Crespo-Leiro MG. Beta-Blocker Exposure and Survival in Patients With Transthyretin Amyloid Cardiomyopathy. Mayo Clin Proc. 2022 Feb;97(2):261-273. Epub 2021 Nov 19. PMID: 34802727. https://doi.org/10.1016/j.mayocp.2021.08.006

202. Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, Palumbo A, Jagannath S, Blade J, Lonial S, Dimopoulos M, Comenzo R, Einsele H, Barlogie B, Anderson K, Gertz M, Harousseau JL, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Richardson P, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Rajkumar SV, Durie BG; International Myeloma Working Group. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009 Feb;23(2):215-24. https://doi.org/10.1038/leu.2008.307

203. Клинические рекомендации Минздрава России «Другие плазмоклеточные новообразования», 2024 г https://cr.minzdrav.gov.ru/view-cr/883_1

204. Lang FM, Teruya S, Cuomo M, Santos AM, Radhakrishnan J, Lentzsch S, Chakraborty R, Bhutani D, Maurer MS. Safety and Efficacy of SGLT2 Inhibitors for Amyloid Light-Chain Cardiomyopathy. J Card Fail. 2024 Dec;30(12):1641-1646. https://doi.org/10.1016/j.cardfail.2024.06.009

205. Kumar SK, Callander NS, Adekola K, Anderson LD Jr, Baljevic M, Campagnaro E, Castillo JJ, Costello C, D'Angelo C, Devarakonda S, Elsedawy N, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Lee HC, Liedtke M, Martin T, Omel J, Rosenberg A, Sborov D, Valent J, Berardi R, Kumar R. Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 Jan;21(1):67-81. PMID: 36652935. https://doi.org/10.6004/jnccn.2023.0001

206. Wechalekar AD, Cibeira MT, Gibbs SD, Jaccard A, Kumar S, Merlini G, Palladini G, Sanchorawala V, Schönland S, Venner C, Boccadoro M, Kastritis E. Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group. Amyloid. 2023 Mar;30(1):3-17. https://doi.org/10.1080/13506129.2022.2093635

207. Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Sanchorawala V, Gibbs S, Mollee P, Venner CP, Lu J, Schönland S, Gatt ME, Suzuki K, Kim K, Cibeira MT, Beksac M, Libby E, Valent J, Hungria V, Wong SW, Rosenzweig M, Bumma N, Huart A, Dimopoulos MA, Bhutani D, Waxman AJ, Goodman SA, Zonder JA, Lam S, Song K, Hansen T, Manier S, Roeloffzen W, Jamroziak K, Kwok F, Shimazaki C, Kim JS, Crusoe E, Ahmadi T, Tran N, Qin X, Vasey SY, Tromp B, Schecter JM, Weiss BM, Zhuang SH, Vermeulen J, Merlini G, Comenzo RL; ANDROMEDA Trial Investigators. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. N Engl J Med. 2021 Jul 1;385(1):46-58. https://doi.org/10.1056/NEJMoa2028631

208. Sanchorawala V. Summary of the EHA-ISA Working Group Guidelines for High-dose Chemotherapy and Stem Cell Transplantation for Systemic AL Amyloidosis. Hemasphere. 2022 Jan 27;6(2):e681. https://doi.org/10.1097/HS9.0000000000000681.

209. Liu B, Wang Y, Ning X, Bai M, Wang D, Zhao J, Zhou M, Sun S. A comparative study of cyclophosphamide, thalidomide and dexamethasone (CTD) versus bortezomib and dexamethasone (BDex) in light-chain amyloidosis. Curr Probl Cancer. 2021 Apr;45(2):100669. https://doi.org/10.1016/j.currproblcancer.2020.100669

210. Kastritis E, Leleu X, Arnulf B, et al. Bortezomib, melphalan and dexamethasone for light chain amyloidosis. J Clin Oncol. 2020; 38(28): 3252-3260. https://doi.org/10.1200/jco.20.01285

211. Schwotzer R, Flammer AJ, Gerull S, Pabst T, Arosio P, Averaimo M, Bacher VU, Bode P, Cavalli A, Concoluci A, Dirnhofer S, Djerbi N, Dobner SW, Fehr T, Garofalo M, Gaspert A, Heimgartner R, Hübers A, Jung HH, Kessler C, Knöpfel R, Laptseva N, Manka R, Mazzucchelli L, Meyer M, Mihaylova V, Monney P, Mylonas A, Nkoulou R, Pazhenkottil A, Pfister O, Rüfer A, Schmidt A, Seeger H, Stämpfli SF, Stirnimann G, Suter T, Théaudin M, Treglia G, Tzankov A, Vetter F, Zweier M, Gerber B. Expert recommendation from the Swiss Amyloidosis Network (SAN) for systemic AL-amyloidosis. Swiss Med Wkly. 2020 Dec 5;150:w20364. https://doi.org/10.4414/smw.2020.20364

212. Palladini G, Milani P, Foli A. et al. Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case–control study on 174 patients. Leukemia. 2014;28:2311-2316. https://doi.org/10.1038/leu.2014.227

213. Р Рехтина И.Г., Менделеева Л.П. Современные критерии диагностики AL-амилоидоза. Врач. 2022;33(7):82-86. https://doi.org/10.29296/25877305-2022-07-17

214. Kumar SK, Hayman SR, Buadi FK, et al. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for lightchain amyloidosis: long term results from a phase 2 trial. Blood. 2012;119:4860-4867. https://doi.org/10.1182/blood-2012-01-407791

215. Palladini, G., Russo, P., Foli, A. et al. Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide. Ann Hematol . 2012 Jan;91(1):89-92. https://doi.org/10.1007/s00277-011-1244-x

216. Kastritis E, Minnema C, Dimopoulos M, et al. Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network. (ASH Annual Meeting Abstracts). 2022;2730.

217. Manwani R, Cohen O, Sharpley F, et al. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood. 2019;134(25):2271-2280. https://doi.org/10.1182/blood.2019000834

218. Fotiou D, Dimopoulos MA, Kastritis E. Systemic AL Amyloidosis: Current Approaches to Diagnosis and Management. Hemasphere. 2020; 4(4):e454. https://doi.org/10.1097/hs9.0000000000000454

219. Gertz MA, Lacy MQ, Dispenzieri A, et al. Trends in day 100 and 2-year survival after auto- SCT for AL amyloidosis: outcomes before and after 2006. Bone Marrow Transplant. 2011; 46:970-975. https://doi.org/10.1038/bmt.2010.234

220. Sidiqi MH, Aljama MA, Buadi FK, et al. Stem cell transplantation for light chain amyloidosis: decreased early mortality over time. J Clin Oncol. 2018;36(13):1323-9. https://doi.org/10.1200/jco.2017.76.9554

221. Sidana S, Sidiqi MH, Dispenzieri A, et al. Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. Am J Hematol. 2019;94(9):1020-6. https://doi.org/10.1002/ajh.25566

222. Roussel M, Merlini G, Chevret S, et al. A prospective phase 2 trial of daratumumab in patients with previously treated systemic lightchain amyloidosis. Blood . 2020 Apr 30;135(18):1531-1540. https://doi.org/10.1182/blood.2019004369

223. Milani P, Sharpley F, Schönland SO, et al. Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients. Amyloid. 2020;27(4):231-236. https://doi.org/10.1080/13506129.2020.1767566

224. Solomon A, Weiss DT, Wall JS. Immunotherapy in systemic primary (AL) amyloidosis using amyloid-reactive monoclonal antibodies. Cancer Biother Radiopharm. 2003 Dec;18(6):853-60. https://doi.org/10.1089/108497803322702824

225. Popkova T, Hajek R, Jelinek T. Monoclonal antibodies in the treatment of AL amyloidosis: co-targetting the plasma cell clone and amyloid deposits. Br J Haematol. 2020 Apr;189(2):228-238. https://doi.org/10.1111/bjh.16436